Results 191 to 200 of about 17,208,238 (361)

Structure-activity relationship of GSK-3β inhibitors: insight into drug design for Alzheimer's disease. [PDF]

RSC Med Chem
Rajamani G, Naqvi S, Sharma A.
europepmc   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Structural biology of HIV-1 reverse transcriptase allosteric inhibitors for drug design. [PDF]

Acta Pharm Sin B
Zhou Z, Sun Y, Feng D, Wang Z, Zhao F, Gao S, Zhan P, Kang D, Liu X.   +8 more
europepmc   +1 more source

Drug Design: Indole Derivatives as Indoleamine 2,3-Dioxygenase-1 Enzyme Inhibition Using In Silico Approach [PDF]

Imam Siswanto, Muhammad Ikhlas Abdjan, Nanik Siti Aminah, Alfinda Novi Kristanti, Khusna Arif Rakhman, I Gusti Made Sanjaya, Muggundha Raoov, Yoshiaki Takaya   +7 more
openalex   +1 more source

Impact of gastrointestinal disease states on oral drug absorption – implications for formulation design – a PEARRL review [PDF]

, 2018
Angela Effinger, Caitríona M. O’Driscoll, Mark McAllister, Nikoletta Fotaki   +3 more
openalex   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

In Search of Beautiful Molecules: A Perspective on Generative Modeling for Drug Design. [PDF]

J Chem Inf Model
van den Broek RL, Patel S, van Westen GJP, Jespers W, Sherman W.   +4 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Standards for Computational Methods in Drug Design and Discovery: Simplified Guidance for Authors and Reviewers. [PDF]

Drug Des Devel Ther
Ibrahim TM, Hussain M, Boeckler FM.
europepmc   +1 more source

Unify Markov model for Rational Design and Synthesis of More Safe Drugs. Predicting Multiple Drugs Side Effects

, 2005
Humberto González‐Díaz, Maykel Cruz‐Monteagudo, Miguel Ángel Cabrera‐Pérez, Reinaldo Molina, Yunierkis Pérez‐Castillo   +4 more
openalex   +2 more sources